Packaging

Microfluidics Increases Already Sizable Presence in Europe, Middle East and Africa

Friday 17. October 2008 - Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation (OTCBB: MFLU), has implemented new initiatives in order to better meet the needs of the growing biotechnology, pharmaceutical, chemical, cosmetics/personal care and food industries beyond the boundaries of North America, and to satisfy the increasing global demand for the company's innovative Microfluidizer high shear fluid processors.

Microfluidics has maintained a presence in Europe, the Middle East and Africa (EMEA) since the mid-90’s, through in-country sales representatives managed from a central sales office in Germany. As part of the first phase of its global distribution expansion plans, the company is now increasing that presence with new sales representatives and partnerships in France, Jordan, Kazakhstan, Portugal, Russia, Switzerland and Ukraine. “We see tremendous opportunities for short- and long-term growth in all industries we currently serve throughout EMEA, as new applications requiring high quality and stable particle size reduction show up every day” said Xavier Leroy, Microfluidics’ Vice President of Sales for Europe, Middle East and Africa. “By escalating our sales and service presence in these regions, we will be better equipped to meet the ever-increasing demand for our Microfluidizer processors and to help our customers in these countries achieve success with their own products and applications.” Microfluidics has amplified its sales force in EMEA with the addition of sales and service professionals who are not only knowledgeable about current market segments’ needs and trends, but who also have a complete understanding of the cultures, economies and languages in the countries that they serve. Additionally, Microfluidics runs a testing lab at its EMEA sales office in Lampertheim, Germany where prospects from throughout the region can determine how a Microfluidizer processor would address their formulation challenges.